LCCC 0412: PHASE I CARBOPLATIN AND ABRAXANE IN PATIENTS WITH SOLID TUMORS

LCCC 0412：I 期卡铂和 ABRAXANE 用于实体瘤患者

• 批准号: 7377549
• 负责人: Thomas Stinchcombe
• 金额: $ 9.61万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377549
• 关键词: LCCC; 0412; PHASE; CARBOPLATIN; ABRAXANE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine highest dose of Abraxane that can be safely given with carboplatin when Abraxane is given once a week or every 3 weeks.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是确定当Abraxane每周一次或每3周一次给药时，可以与卡铂一起安全给予的Abraxane的最高剂量。